Results 1 to 10 of about 17,138 (209)

Hydrogel-Based Strategies for the Prevention and Treatment of Radiation-Induced Skin Injury: Progress and Mechanistic Insights

Biomimetics
Radiation-induced skin injury (RISI) is one of the most common complications of radiotherapy, severely compromising patients’ quality of life. However, no standardized treatment has yet been established.
Yinhui Wang, Huan Liu, Yushan He, Mei Li, Jie Gao, Zongtai Han, Jiayu Zhou, Jianguo Li   +7 more
doaj   +1 more source

Optimized production of 89Zr as a medical radioisotope on a variable energy cyclotron and external beam-line

EJNMMI Physics
Background Zirconium-89 (89Zr) is a highly valued diagnostic radionuclide for positron emission tomography (PET) due to its long physical half-life of 78.4 h and decay characteristics, being preferred for the radiolabelling of nanoparticles and slow ...
Diana Cocioabă, Simona Baruta, Liviu Crăciun, Radu Leonte, Andrei Necsoiu, Maria-Roxana Tudoroiu-Cornoiu, Alexandru Jipa, Dana Niculae   +7 more
doaj   +1 more source

Chelator impact: investigating the pharmacokinetic behavior of copper-64 labeled PD-L1 radioligands

EJNMMI Radiopharmacy and Chemistry
Background Programmed cell death ligand 1 (PD-L1) plays a critical role in the tumor microenvironment and overexpression in several solid cancers has been reported. This was associated with a downregulation of the local immune response, specifically of T-
Fabian Krutzek, Cornelius K. Donat, Sven Stadlbauer   +2 more
doaj   +1 more source

In Vitro Characterization of the Published Glypican-3-Targeting Peptide TJ12P2 Reveals a Lack of Specificity and Potency

Pharmaceuticals
Background/Objectives: The cell surface proteoglycan glypican-3 (GPC3) is reportedly overexpressed in hepatocellular carcinoma (HCC) tissues, but not in benign liver tissues, rendering this protein a potential target for radionuclide theranostic ...
Eva-Maria Burger, Charlice Hill, Robert Wodtke, Kristof Zarschler, Markus Laube, Cornelius K. Donat, Sandra Hauser, Klaus Kopka, Jens Pietzsch, Sven Stadlbauer   +9 more
doaj   +1 more source

Terbium-149 production: a focus on yield and quality improvement towards preclinical application

Scientific Reports
Terbium-149 (T1/2 = 4.1 h, Eα = 3.98 MeV (16.7%), 28 µm range in tissue) is a radionuclide with potential for targeted alpha therapy. Due to the negligible emission of α-emitting daughter nuclides, toxicity to healthy tissue may be reduced in comparison ...
C. Favaretto, P. V. Grundler, Z. Talip, U. Köster, K. Johnston, S. D. Busslinger, P. Sprung, C. C. Hillhouse, R. Eichler, R. Schibli, C. Müller, N. P. van der Meulen   +11 more
doaj   +1 more source

Toward Personalized Immunotherapeutic Drug Monitoring with Multiplexed Extended‐Gate Field‐Effect‐Transistor Biosensors

Small Science
The selection and optimization of therapies for cancer patients urgently need personalization. Portable point‐of‐care electronic biosensors emerge as a groundbreaking solution contributing to better decision‐making in precision oncology.
Trang‐Anh Nguyen‐Le, Christin Neuber, Isli Cela, Željko Janićijević, Liliana Rodrigues Loureiro, Lydia Hoffmann, Anja Feldmann, Michael Bachmann, Larysa Baraban   +8 more
doaj   +1 more source

Repurposing radiopharmaceutical carriers for targeted drug delivery and theranostics: A translational framework. [PDF]

Pharm Sci Adv
Shahiwala AF.
europepmc   +1 more source

Correction: Eroglu et al. Biodistribution of Tc-99m-Labeled Solid Lipid Nanoparticles and Evaluation of Their Possibility as a Radiopharmaceutical. <i>Molecules</i> 2026, <i>31</i>, 654. [PDF]

Molecules
Eroglu H, Ayan AK, Yenilmez A.
europepmc   +1 more source

Real-time detection of extravasation events of diagnostic and therapeutic radiopharmaceuticals in oncology. [PDF]

PLoS One
Cucurachi N, Fioroni F, Grassi E, Panico N, Verzellesi L, Botti A, Fraternali A, Roncali M, Durmo R, Filice A, Iori M.   +10 more
europepmc   +1 more source

Using advanced cell models for targeted radionuclide therapy evaluation: increased efficacy in 3D versus 2D. [PDF]

EJNMMI Res
Klomp MJ, Erkens SE, van den Brink L, van Weerden WM, Dalm SU.   +4 more
europepmc   +1 more source